Lipoprotein(a): A promising marker for residual cardiovascular risk assessment

Disease Markers

Volumn 35, Issue 5, 2013, Pages 551-559

  Cai, Anping ^a   Li, Liwen ^a   Zhang, Ying ^a   Mo, Yujin ^a   Mai, Weiyi ^b   Zhou, Yingling ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE MARKER; DNA POLYMORPHISM; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; HUMANS; LIPOPROTEIN(A); RISK ASSESSMENT;

EID: 84890372414     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/563717     Document Type: Review

References (112)

1. C. M. Gibson, Y. B. Pride, C. P. Hochberg, S. Sloan, M. S. Sabatine, and C. P. Cannon, "Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCIPROVE IT: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and InfectionTherapy-Thrombolysis in Myocardial Infarction 22) substudy," Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2290-2295, 2009.
2. P. M. Kearney, L. Blackwell, R. Collins et al., "Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: ameta-analysis," The Lancet, vol. 371, no. 9607, pp. 117-125, 2008.
3. C. P. Cannon, B. A. Steinberg, S. A. Murphy, J. L. Mega, and E. Braunwald, "Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy," Journal of the American College of Cardiology, vol. 48, no. 3, pp. 438-445, 2006.
4. J. Armitage, L. Bowman, K. Wallendszus et al., "Intensive lowering of LDL cholesterol with 80mg versus 20mg simvastatin daily in 12, 064 survivors of myocardial infarction: a doubleblind randomised trial," The Lancet, vol. 376, no. 9753, pp. 1658-1669, 2010.
5. C. Baigent, L. Blackwell, J. Emberson et al., "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials," The Lancet, vol. 376, no. 9753, pp. 1670-1681, 2010.
6. C. P. Cannon, E. Braunwald, C. H. McCabe et al., "Intensive versus moderate lipid lowering with statins after acute coronary syndromes,"The New England Journal of Medicine, vol. 350, no. 15, pp. 1495-1504, 2004.
7. J. C. LaRosa, S. M. Grundy, D. D. Waters et al., "Intensive lipid loweringwith atorvastatin in patients with stable coronary disease,"The New England Journal of Medicine, vol. 352, no. 14, pp. 1425-1435, 2005.
8. M. J. Chapman, "Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention," Cardiovascular Drugs andTherapy, vol. 19, no. 2, pp. 135-139, 2005.
9. M. Schachter, "Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid," Cardiovascular Drugs andTherapy, vol. 19, no. 6, pp. 415-422, 2005.
10. P. K. Shah, "Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease," European Heart Journal, vol. 28, no. 1, pp. 5-12, 2007.
11. C. Y. Campbell, J. J. Rivera, and R. S. Blumenthal, "Residual risk in statin-treated patients: future therapeutic options," Current Cardiology Reports, vol. 9, no. 6, pp. 499-505, 2007.
12. S. M.Marcovina, M. L. Koschinsky, J. J. Albers, and S. Skarlatos, "Report of the NationalHeart, Lung, and Blood InstituteWorkshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions," Clinical Chemistry, vol. 49, no. 11, pp. 1785-1796, 2003.
13. J.Danesh, R. Collins, and R. Peto, "Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies," Circulation, vol. 102, no. 10, pp. 1082-1085, 2000.
14. A. A. Ariyo, C. Thach, and R. Tracy, "Lp(a) lipoprotein, vascular disease, and mortality in the elderly,"The New England Journal of Medicine, vol. 349, no. 22, pp. 2108-2115, 2003.
15. S. Erqou, S. Kaptoge, P. L. Perry et al., "Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality," Journal of the American Medical Association, vol. 302, no. 4, pp. 412-423, 2009.
16. J. Hoover-Plow and M. Huang, "Lipoprotein(a) metabolism: potential sites for therapeutic targets," Metabolism, vol. 62, no. 4, pp. 479-491, 2013.
17. P. R. Kamstrup, "Lipoprotein(a) and ischemic heart disease-a causal association? A review," Atherosclerosis, vol. 211, no. 1, pp. 15-23, 2010.
18. S. M. Marcovina, J. J. Albers, D. R. Jacobs Jr. et al., "Lipoprotein( a) concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans: the CARDIA study," Arteriosclerosis andThrombosis, vol. 13, no. 7, pp. 1037-1045, 1993.
19. J. Rubin, H. J. Kim, T. A. Pearson, S. Holleran, L. Berglund, and R. Ramakrishnan, "The apolipoprotein(a) gene: linkage disequilibria at three loci differs in African Americans and Caucasians," Atherosclerosis, vol. 201, no. 1, pp. 138-147, 2008.
20. E. Boerwinkle, H. J. Menzel, H. G. Kraft, and G. Utermann, "Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation," Human Genetics, vol. 82, no. 1, pp. 73-78, 1989.
21. S. Erqou, A. Thompson, E. Di Angelantonio et al., "Apolipoprotein( a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58, 000 participants," Journal of the American College of Cardiology, vol. 55,no. 19,pp. 2160-2167, 2010.
22. I. Kardys, R. M. Oemrawsingh, I. P. Kay et al., "Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention," Clinical Cardiology, vol. 35, no. 8, pp. 482-489, 2012.
23. Y. Momiyama, R. Ohmori, Z. A. Fayad et al., "Associations between serum lipoprotein(a) levels and the severity of coronary and aortic atherosclerosis," Atherosclerosis, vol. 222, no. 1, pp. 241-244, 2012.
24. D. J. Suk, N. Rifai, and J. E. Buring, "Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events," Journal of the American College of Cardiology, vol. 52, no. 2, pp. 124-131, 2008.
25. M. H.Davidson,C.M. Ballantyne,T. A. Jacobson et al., "Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists," Journal of Clinical Lipidology, vol. 5, no. 5, pp. 338-367, 2011.
26. B. G. Nordestgaard, M. J. Chapman, K. Ray et al., "Lipoprotein( a) as a cardiovascular risk factor: current status," European Heart Journal, vol. 31, no. 23, pp. 2844-2853, 2010.
27. D. I. Chasman, D. Shiffman, R. Y. L. Zee et al., "Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy," Atherosclerosis, vol. 203, no. 2, pp. 371-376, 2009.
28. K. Berg, "A new serum type system in man-the Lp system," Acta Pathologica et Microbiologica Scandinavica, vol. 59, pp. 369-382, 1963.
29. M. L. Koschinsky, G. P. Cote, B. Gabel, and Y. Y. van der Hoek, "Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100," The Journal of Biological Chemistry, vol. 268, no. 26, pp. 19819-19825, 1993.
30. J. W. McLean, J. E. Tomlinson, W.-J. Kuang et al., "cDNA sequence of human apolipoprotein(a) is homologous to plasminogen," Nature, vol. 330, no. 6144, pp. 132-137, 1987.
31. L. A. Miles and E. F. Plow, "Lp(a): an interloper into the fibrinolytic system?" Thrombosis and Haemostasis, vol. 63, no. 3, pp. 331-335, 1990.
32. N. Malgaretti, F. Acquati, P. Magnaghi et al., "Characterization by yeast artificial chromosome cloning of the linked apolipoprotein(a) and plasminogen genes and identification of the apolipoprotein(a) 5′ flanking region," Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 23, pp. 11584-11588, 1992.
33. Y. Y. van der Hoek, M. E. Wittekoek, U. Beisiegel, J. J. P. Kastelein, andM. L.Koschinsky, "The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms," Human Molecular Genetics, vol. 2, no. 4, pp. 361-366, 1993.
34. C. Lackner, J. C. Cohen, and H. H. Hobbs, "Molecular definition of the extreme size polymorphism in apolipoprotein(a)," Human Molecular Genetics, vol. 2, no. 7, pp. 933-940, 1993.
35. L. Berglund and R. Ramakrishnan, "Lipoprotein(a): an elusive cardiovascular risk factor," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 12, pp. 2219-2226, 2004.
36. B. R. Gabel and M. L. Koschinsky, "Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a)," Biochemistry, vol. 34, no. 48, pp. 15777-15784, 1995.
37. G. Utermann, H. J. Menzel, H. G. Kraft, H. C. Duba, H. G. Kemmler, and C. Seitz, "Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma," The Journal of Clinical Investigation, vol. 80, no. 2, pp. 458-465, 1987.
38. M. L. Koschinsky, G. P. Cote, B. Gabel, and Y. Y. van der Hoek, "Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100," The Journal of Biological Chemistry, vol. 268, no. 26, pp. 19819-19825, 1993.
39. L. Becker, P. M. Cook, T. G. Wright, and M. L. Koschinsky, "Quantitative evaluation of the contribution of weak lysinebinding sites present within apolipoprotein(a) kringle IV types 6-8 to lipoprotein(a) assembly," The Journal of Biological Chemistry, vol. 279, no. 4, pp. 2679-2688, 2004.
40. S. M. Marcovina, H. H. Hobbs, and J. J. Albers, "Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature," Clinical Chemistry, vol. 42, no. 3, pp. 436-439, 1996.
41. D. K. Bonen, A. M. L. Hausman, C. Hadjiagapiou, S. F. Skarosi, and N. O. Davidson, "Expression of a recombinant apolipoprotein( a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a)," The Journal of Biological Chemistry, vol. 272, no. 9, pp. 5659-5667, 1997.
42. E. Lobentanz, K. Krasznai, A. Gruber et al., "Intracellular metabolism of human apolipoprotein(a) in stably transfected Hep G2 cells," Biochemistry, vol. 37, no. 16, pp. 5417-5425, 1998.
43. V. N. Trieu and W. J. McConathy, "A two-step model for lipoprotein(a) formation,"The Journal of Biological Chemistry, vol. 270, no. 26, pp. 15471-15474, 1995.
44. S. P. McCormick, "Lipoprotein(a): biology and clinical importance," The Clinical Biochemist Reviews, vol. 25, no. 1, pp. 69-80, 2004.
45. C. Brunner, E. Lobentanz, A. Pethö-Schrammet al., "The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells," The Journal of Biological Chemistry, vol. 271, no. 50, pp. 32403-32410, 1996.
46. D. Boffelli, D. A. Zajchowski, Z. Yang, and R. M. Lawn, "Estrogen modulation of apolipoprotein(a) expression: identification of a regulatory element,"The Journal of Biological Chemistry, vol. 274, no. 22, pp. 15569-15574, 1999.
47. D. P.Wade, J. G. Clarke,G. E. Lindahl et al., "5′ control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 4, pp. 1369-1373, 1993.
48. E. Boerwinkle, C. C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H. H.Hobbs, "Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations," The Journal of Clinical Investigation, vol. 90, no. 1, pp. 52-60, 1992.
49. J. C. Cohen, G. Chiesa, and H. H. Hobbs, "Sequence polymorphisms in the apolipoprotein(a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels," The Journal of Clinical Investigation, vol. 91, no. 4, pp. 1630-1636, 1993.
50. H. H. Hobbs and A. L. White, "Lipoprotein(a): intrigues and insights," Current Opinion in Lipidology, vol. 10, no. 3, pp. 225-236, 1999.
51. L. H. Puckey and B. L. Knight, "Sequence and functional changes in a putative enhancer region upstream of the apolipoprotein(a) gene," Atherosclerosis, vol. 166, no. 1, pp. 119-127, 2003.
52. T.Huby, V. Afzal, C.Doucet et al., "Regulation of the expression of the apolipoprotein(a) gene: evidence for a regulatory role of the 5′ distal apolipoprotein(a) transcription control region enhancer in yeast artificial chromosome transgenic mice," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 9, pp. 1633-1639, 2003.
53. S. L. Hofmann, D. L. Eaton, M. S. Brown,W. J.McConathy, J. L. Goldstein, and R. E. Hammer, "Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice," The Journal of Clinical Investigation, vol. 85, no. 5, pp. 1542-1547, 1990.
54. H. G. Kraft, A. Lingenhel, F. J. Raal, M. Hohenegger, and G. Utermann, "Lipoprotein(a) in homozygous familial hypercholesterolemia," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 20, no. 2, pp. 522-528, 2000.
55. B. L.Knight, Y. F. N. Perombelon,A.K. Soutar, D. P. Wade, and M. Seed, "Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects," Atherosclerosis, vol. 87,no. 2-3, pp. 227-237, 1991.
56. D. J. Rader,W. A.Mann,W.Cain et al., "The lowdensity lipoprotein receptor is not required for normal catabolism of Lp(a) in humans,"The Journal of Clinical Investigation, vol. 95, no. 3, pp. 1403-1408, 1995.
57. K. M. Argraves, K. F. Kozarsky, J. T. Fallon, P. C. Harpel, and D. K. Strickland, "Theatherogenic lipoprotein Lp(a) is internalized and degraded in a processmediated by the VLDL receptor," The Journal of Clinical Investigation, vol. 100, no. 9, pp. 2170-2181, 1997.
58. C. Edelstein, J. A. Italia, and A. M. Scanu, "Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein( a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments," The Journal of Biological Chemistry, vol. 272, no. 17, pp. 11079-11087, 1997.
59. F. Kronenberg, E. Trenkwalder, A. Lingenhel et al., "Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation," Journal of Lipid Research, vol. 38, no. 9, pp. 1755-1763, 1997.
60. L. A. Sechi, L. Zingaro, S. De Carli et al., "Increased serum lipoprotein(a) levels in patients with early renal failure," Annals of Internal Medicine, vol. 129, no. 6, pp. 457-461, 1998.
61. M. E. Frischmann, F. Kronenberg, E. Trenkwalder et al., "In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients," Kidney International, vol. 71, no. 10, pp. 1036-1043, 2007.
62. K.M. Kostner, S. Banyai,M. Banyai et al., "Urinary apolipoprotein( a) excretion in patients with proteinuria," Annals of Medicine, vol. 30, no. 5, pp. 497-502, 1998.
63. K. Oida,H. Takai,H.Maeda et al., "Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure," Clinical Chemistry, vol. 38, no. 11, pp. 2244-2248, 1992.
64. M. B. Boffa, S. M. Marcovina, and M. L. Koschinsky, "Lipoprotein( a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights fromanimal models," Clinical Biochemistry, vol. 37, no. 5, pp. 333-343, 2004.
65. M. L. Koschinsky and S. M. Marcovina, "Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity," CurrentOpinion in Lipidology, vol. 15, no. 2, pp. 167-174, 2004.
66. F. Kronenberg, M. F. Kronenberg, S. Kiechl et al., "Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results fromthe bruneck study," Circulation, vol. 100, no. 11, pp. 1154-1160, 1999.
67. J. Danesh and S. Erqou, "Risk factors: lipoprotein(a) and coronary disease-moving closer to causality," Nature Reviews, vol. 6, no. 9, pp. 565-567, 2009.
68. S. Tsimikas and J. L. Witztum, "The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity," Current Opinion in Lipidology, vol. 19, no. 4, pp. 369-377, 2008.
69. S. Tsimikas, J. L. Witztum, E. R. Miller et al., "High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial," Circulation, vol. 110, no. 11, pp. 1406-1412, 2004.
70. S. Tsimikas, S. Kiechl, J. Willeit et al., "Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: fiveyear prospective results from the Bruneck study," Journal of the American College of Cardiology, vol. 47, no. 11, pp. 2219-2228, 2006.
71. S. Tsimikas, E. S. Brilakis, E. R.Miller et al., "Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease," The New England Journal of Medicine, vol. 353, no. 1, pp. 46-57, 2005.
72. S. Tsimikas, C. Bergmark, R. W. Beyer et al., "Temporal increases in plasmamarkers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes," Journal of the American College of Cardiology, vol. 41, no. 3, pp. 360-370, 2003.
73. S. Tsimikas, H. K. Lau, K. Han et al., "Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein," Circulation, vol. 109, no. 25, pp. 3164-3170, 2004.
74. S. Karabina and E. Ninio, "Plasma PAF-acetylhydrolase: an unfulfilled promise?" Biochimica et Biophysica Acta, vol. 1761, no. 11, pp. 1351-1358, 2006.
75. E.Morgan, E.M. Boyle Jr.,W.Yun et al., "Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury," Circulation, vol. 100, supplement 19, pp. II365-II368, 1999.
76. R. Quarck, B. De Geest, D. Stengel et al., "Adenovirusmediated gene transfer of human platelet-activating factoracetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein Edeficient mice," Circulation, vol. 103, no. 20, pp. 2495-2500, 2001.
77. G. Theilmeier, B. De Geest, P. P. van Veldhoven et al., "HDLassociated PAF-AH reduces endothelial adhesiveness in apoE(-/-) mice," The FASEB Journal, vol. 14, no. 13, pp. 2032-2039, 2000.
78. H. Noto, M. Hara, K. Karasawa et al., "Human plasma plateletactivating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 829-835, 2003.
79. M. J. Caslake, C. J. Packard, K. E. Suckling, S. D. Holmes, P. Chamberlain, and C. H. Macphee, "Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease," Atherosclerosis, vol. 150, no. 2, pp. 413-419, 2000.
80. R. S. Rosenson, "Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes," Current Opinion in Lipidology, vol. 21, no. 6, pp. 473-480, 2010.
81. D.Mannheim, J.Herrmann,D.Versari et al., "Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques," Stroke, vol. 39, no. 5, pp. 1448-1455, 2008.
82. S. Blankenberg, D. Stengel, H. J. Rupprecht et al., "Plasma PAFacetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis," Journal of Lipid Research, vol. 44, no. 7, pp. 1381-1386, 2003.
83. T. R. Pedersen, "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)," The Lancet, vol. 344, no. 8934, pp. 1383-1389, 1994.
84. A. Cai, D. Zheng, R. Qiu, W. Mai, and Y. Zhou, " Lipoproteinassociated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment," Disease Markers, vol. 34, no. 5, pp. 323-331, 2013.
85. V. Nambi and C. M. Ballantyne, "Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events," Current Atherosclerosis Reports, vol. 8, no. 5, pp. 374-381, 2006.
86. L. D. Tsironis, C. S. Katsouras, E. S. Lourida et al., "Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease," Atherosclerosis, vol. 177, no. 1, pp. 193-201, 2004.
87. S. Tsimikas, L. D. Tsironis, and A. D. Tselepis, "New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 27, no. 10, pp. 2094-2099, 2007.
88. L. Hervio, A. Girard-Globa, V. Durlach, and E. Anglés-Cano, "The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin," European Journal of Clinical Investigation, vol. 26, no. 5, pp. 411-417, 1996.
89. S. Erqou, A. Thompson, E. Di Angelantonio et al., "Apolipoprotein( a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58, 000 participants," Journal of the American College of Cardiology, vol. 55,no. 19,pp. 2160-2167, 2010.
90. J. S. Danik, N. Rifai, J. E. Buring, and P. M. Ridker, "Lipoprotein( a), measured with an assay independent of apolipoprotein( a) isoform size, and risk of future cardiovascular events among initially healthy women," Journal of the American Medical Association, vol. 296, no. 11, pp. 1363-1370, 2006.
91. N. Rifai, J. Ma, F. M. Sacks et al., "Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the physicians' health study," Clinical Chemistry, vol. 50, no. 8, pp. 1364-1371, 2004.
92. P. R. Kamstrup, A. Tybjærg-Hansen, R. Steffensen, and B. G. Nordestgaard, "Genetically elevated lipoprotein(a) and increased risk ofmyocardial infarction," Journal of theAmerican Medical Association, vol. 301, no. 22, pp. 2331-2339, 2009.
93. J.-P. Chretien, J. Coresh, Y. Berthier-Schaad et al., "Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans," Journal of Medical Genetics, vol. 43, no. 12, pp. 917-923, 2006.
94. M. B. Lanktree, S. S. Anand, S. Yusuf, and R. A. Hegele, "Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians," Circulation, vol. 3, no. 1, pp. 39-46, 2010.
95. R. Clarke, J. F. Peden, J. C. Hopewell et al., "Genetic variants associated with Lp(a) lipoprotein level and coronary disease," The New England Journal ofMedicine, vol. 361, no. 26, pp. 2518-2528, 2009.
96. S. Erqou, A. Thompson, E. Di Angelantonio et al., "Apolipoprotein( a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58, 000 participants," Journal of the American College of Cardiology, vol. 55,no. 19,pp. 2160-2167, 2010.
97. Y.Li,M.M. Luke,D.Shiffman, and J. J.Devlin, "Genetic variants in the apolipoprotein(a) gene and coronary heart disease," Circulation, vol. 4, no. 5, pp. 565-573, 2011.
98. M. M. Luke, J. P. Kane, D. M. Liu et al., "A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 9, pp. 2030-2036, 2007.
99. D. Shiffman, E. S. O'Meara, L. A. Bare et al., "Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 28, no. 1, pp. 173-179, 2008.
100. J. C.Hopewell,R.Clarke, S. Parish et al., "Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the heart protection study," Circulation, vol. 4, no. 1, pp. 68-73, 2011.
101. D. Shiffman, J. Z. Louie, C. M. Rowland, M. J. Malloy, J. P. Kane, and J. J. Devlin, "Single variants can explain the association between coronary heart disease and haplotypes in the apolipoprotein(a) locus," Atherosclerosis, vol. 212, no. 1, pp. 193-196, 2010.
102. L. A. Carlson, A. Hamsten, andA.Asplund, "Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid," Journal of Internal Medicine, vol. 226, no. 4, pp. 271-276, 1989.
103. G. B. Vigna, P. Donegà, R. Zanca et al., "Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in earlypostmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial," Metabolism, vol. 51, no. 11, pp. 1463-1470, 2002.
104. M. Taskinen, J. Puolakka, T. Pyörälä et al., "Hormone replacement therapy lowers plasma Lp(a) concentrations: comparison of cyclic transdermal and continuous estrogen-progestin regimens," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 10, pp. 1215-1221, 1996.
105. I. F. Godsland, "Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000," Fertility and Sterility, vol. 75, no. 5, pp. 898-915, 2001.
106. E. Bruckert, J. Labreuche, and P. Amarenco, "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis," Atherosclerosis, vol. 210, no. 2, pp. 353-361, 2010.
107. M. G. Shlipak, J. A. Simon, E. Vittinghoff et al., "Estrogen and progestin, lipoprotein(a) and the risk of recurrent coronary heart disease events after menopause," Journal of the American Medical Association, vol. 283, no. 14, pp. 1845-1852, 2000.
108. G. Lippi and G. Targher, "Optimal therapy for reduction of lipoprotein(a)," Journal of Clinical Pharmacy and Therapeutics, vol. 37, no. 1, pp. 1-3, 2012.
109. R. Ramharack, D. Barkalow, and M. A. Spahr, "Dominant negative effect of TGF-α1 and TNF-β on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 6, pp. 984-990, 1998.
110. O. Schultz, F. Oberhauser, J. Saech et al., "Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (A) levels in human subjects with rheumatoid diseases," PLoS ONE, vol. 5, no. 12, Article IDe14328, 2010.
111. J. M. McKenney, M. J. Koren, D. J. Kereiakes, C. Hanotin, A. Ferrand, and E. A. Stein, "Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy," Journal of the American College of Cardiology, vol. 59, no. 25, pp. 2344-2353, 2012.
112. G. Lippi, M. Franchini, and G. Targher, "Platelets and lipoprotein( a) in retinal vein occlusion: mutual targets for aspirin therapy," Thrombosis and Haemostasis, vol. 97, no. 6, pp. 1059-1060, 2007.